Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
61
IVBXF Quote, Financials, Valuation and Earnings
Last price:
$11.30
Seasonality move
:
6.47%
Day range:
$10.50 - $10.89
52-week range:
$4.69 - $15.12
Dividend yield:
0%
P/E ratio:
108.69x
P/S ratio:
11.47x
P/B ratio:
10.65x
Volume:
4.5K
Avg. volume:
1.6K
1-year change:
97.6%
Market cap:
$18.6B
Revenue:
$1.3B
EPS (TTM):
$0.10
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IVBXF
Innovent Biologics, Inc.
|
-- | -- | -- | -- | -- |
|
CSPCY
CSPC Pharmaceutical Group Ltd.
|
-- | -- | -- | -- | -- |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -- | -- | -- |
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
-- | -- | -- | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$122.7M | -$0.42 | 17.43% | -30.7% | $43.42 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IVBXF
Innovent Biologics, Inc.
|
$10.89 | -- | $18.6B | 108.69x | $0.00 | 0% | 11.47x |
|
CSPCY
CSPC Pharmaceutical Group Ltd.
|
$4.80 | -- | $13.7B | 23.23x | $0.07 | 2.56% | 3.84x |
|
SVA
Sinovac Biotech Ltd.
|
$6.47 | -- | $464.9M | -- | $55.00 | 0% | 1.50x |
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
$10.24 | -- | $20.8B | 29.93x | $0.00 | 0% | 7.73x |
|
ZLAB
Zai Lab Ltd.
|
$19.69 | $43.42 | $2.2B | -- | $0.00 | 0% | 4.78x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IVBXF
Innovent Biologics, Inc.
|
17.68% | 1.263 | -- | 2.16x |
|
CSPCY
CSPC Pharmaceutical Group Ltd.
|
1.2% | 0.343 | -- | 1.93x |
|
SVA
Sinovac Biotech Ltd.
|
3.46% | 7.263 | 12.91% | 11.22x |
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
5.93% | -0.126 | -- | 1.98x |
|
ZLAB
Zai Lab Ltd.
|
22.4% | -0.192 | 5.85% | 2.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IVBXF
Innovent Biologics, Inc.
|
-- | -- | -0.6% | -0.75% | -- | -- |
|
CSPCY
CSPC Pharmaceutical Group Ltd.
|
$646.8M | $205.9M | 12.94% | 12.37% | 25.7% | -- |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -1.02% | -1.05% | -- | -- |
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
-- | -- | 7.16% | 7.53% | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$69.3M | -$48.9M | -21.74% | -26.7% | -42.05% | -$44.5M |
Innovent Biologics, Inc. vs. Competitors
-
Which has Higher Returns IVBXF or CSPCY?
CSPC Pharmaceutical Group Ltd. has a net margin of -- compared to Innovent Biologics, Inc.'s net margin of 21.07%. Innovent Biologics, Inc.'s return on equity of -0.75% beat CSPC Pharmaceutical Group Ltd.'s return on equity of 12.37%.
Company Gross Margin Earnings Per Share Invested Capital IVBXFInnovent Biologics, Inc.-- -- $2.2B CSPCYCSPC Pharmaceutical Group Ltd.67.08% $0.07 $4.7B -
What do Analysts Say About IVBXF or CSPCY?
Innovent Biologics, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand CSPC Pharmaceutical Group Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Innovent Biologics, Inc. has higher upside potential than CSPC Pharmaceutical Group Ltd., analysts believe Innovent Biologics, Inc. is more attractive than CSPC Pharmaceutical Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings IVBXFInnovent Biologics, Inc.0 0 0 CSPCYCSPC Pharmaceutical Group Ltd.0 0 0 -
Is IVBXF or CSPCY More Risky?
Innovent Biologics, Inc. has a beta of 0.054, which suggesting that the stock is 94.576% less volatile than S&P 500. In comparison CSPC Pharmaceutical Group Ltd. has a beta of 0.549, suggesting its less volatile than the S&P 500 by 45.07%.
-
Which is a Better Dividend Stock IVBXF or CSPCY?
Innovent Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CSPC Pharmaceutical Group Ltd. offers a yield of 2.56% to investors and pays a quarterly dividend of $0.07 per share. Innovent Biologics, Inc. pays -- of its earnings as a dividend. CSPC Pharmaceutical Group Ltd. pays out 52% of its earnings as a dividend. CSPC Pharmaceutical Group Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios IVBXF or CSPCY?
Innovent Biologics, Inc. quarterly revenues are --, which are smaller than CSPC Pharmaceutical Group Ltd. quarterly revenues of $964.2M. Innovent Biologics, Inc.'s net income of -- is lower than CSPC Pharmaceutical Group Ltd.'s net income of $203.2M. Notably, Innovent Biologics, Inc.'s price-to-earnings ratio is 108.69x while CSPC Pharmaceutical Group Ltd.'s PE ratio is 23.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovent Biologics, Inc. is 11.47x versus 3.84x for CSPC Pharmaceutical Group Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IVBXFInnovent Biologics, Inc.11.47x 108.69x -- -- CSPCYCSPC Pharmaceutical Group Ltd.3.84x 23.23x $964.2M $203.2M
-
Which has Higher Returns IVBXF or SVA?
Sinovac Biotech Ltd. has a net margin of -- compared to Innovent Biologics, Inc.'s net margin of --. Innovent Biologics, Inc.'s return on equity of -0.75% beat Sinovac Biotech Ltd.'s return on equity of -1.05%.
Company Gross Margin Earnings Per Share Invested Capital IVBXFInnovent Biologics, Inc.-- -- $2.2B SVASinovac Biotech Ltd.-- -- $11.8B -
What do Analysts Say About IVBXF or SVA?
Innovent Biologics, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Innovent Biologics, Inc. has higher upside potential than Sinovac Biotech Ltd., analysts believe Innovent Biologics, Inc. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings IVBXFInnovent Biologics, Inc.0 0 0 SVASinovac Biotech Ltd.0 0 0 -
Is IVBXF or SVA More Risky?
Innovent Biologics, Inc. has a beta of 0.054, which suggesting that the stock is 94.576% less volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.746, suggesting its less volatile than the S&P 500 by 25.394%.
-
Which is a Better Dividend Stock IVBXF or SVA?
Innovent Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. Innovent Biologics, Inc. pays -- of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend.
-
Which has Better Financial Ratios IVBXF or SVA?
Innovent Biologics, Inc. quarterly revenues are --, which are smaller than Sinovac Biotech Ltd. quarterly revenues of --. Innovent Biologics, Inc.'s net income of -- is lower than Sinovac Biotech Ltd.'s net income of --. Notably, Innovent Biologics, Inc.'s price-to-earnings ratio is 108.69x while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovent Biologics, Inc. is 11.47x versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IVBXFInnovent Biologics, Inc.11.47x 108.69x -- -- SVASinovac Biotech Ltd.1.50x -- -- --
-
Which has Higher Returns IVBXF or WXXWY?
WuXi Biologics (Cayman), Inc. has a net margin of -- compared to Innovent Biologics, Inc.'s net margin of --. Innovent Biologics, Inc.'s return on equity of -0.75% beat WuXi Biologics (Cayman), Inc.'s return on equity of 7.53%.
Company Gross Margin Earnings Per Share Invested Capital IVBXFInnovent Biologics, Inc.-- -- $2.2B WXXWYWuXi Biologics (Cayman), Inc.-- -- $6.6B -
What do Analysts Say About IVBXF or WXXWY?
Innovent Biologics, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand WuXi Biologics (Cayman), Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Innovent Biologics, Inc. has higher upside potential than WuXi Biologics (Cayman), Inc., analysts believe Innovent Biologics, Inc. is more attractive than WuXi Biologics (Cayman), Inc..
Company Buy Ratings Hold Ratings Sell Ratings IVBXFInnovent Biologics, Inc.0 0 0 WXXWYWuXi Biologics (Cayman), Inc.0 0 0 -
Is IVBXF or WXXWY More Risky?
Innovent Biologics, Inc. has a beta of 0.054, which suggesting that the stock is 94.576% less volatile than S&P 500. In comparison WuXi Biologics (Cayman), Inc. has a beta of -0.062, suggesting its less volatile than the S&P 500 by 106.225%.
-
Which is a Better Dividend Stock IVBXF or WXXWY?
Innovent Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. WuXi Biologics (Cayman), Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innovent Biologics, Inc. pays -- of its earnings as a dividend. WuXi Biologics (Cayman), Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IVBXF or WXXWY?
Innovent Biologics, Inc. quarterly revenues are --, which are smaller than WuXi Biologics (Cayman), Inc. quarterly revenues of --. Innovent Biologics, Inc.'s net income of -- is lower than WuXi Biologics (Cayman), Inc.'s net income of --. Notably, Innovent Biologics, Inc.'s price-to-earnings ratio is 108.69x while WuXi Biologics (Cayman), Inc.'s PE ratio is 29.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovent Biologics, Inc. is 11.47x versus 7.73x for WuXi Biologics (Cayman), Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IVBXFInnovent Biologics, Inc.11.47x 108.69x -- -- WXXWYWuXi Biologics (Cayman), Inc.7.73x 29.93x -- --
-
Which has Higher Returns IVBXF or ZLAB?
Zai Lab Ltd. has a net margin of -- compared to Innovent Biologics, Inc.'s net margin of -30.98%. Innovent Biologics, Inc.'s return on equity of -0.75% beat Zai Lab Ltd.'s return on equity of -26.7%.
Company Gross Margin Earnings Per Share Invested Capital IVBXFInnovent Biologics, Inc.-- -- $2.2B ZLABZai Lab Ltd.59.62% -$0.33 $979.3M -
What do Analysts Say About IVBXF or ZLAB?
Innovent Biologics, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Zai Lab Ltd. has an analysts' consensus of $43.42 which suggests that it could grow by 120.52%. Given that Zai Lab Ltd. has higher upside potential than Innovent Biologics, Inc., analysts believe Zai Lab Ltd. is more attractive than Innovent Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IVBXFInnovent Biologics, Inc.0 0 0 ZLABZai Lab Ltd.8 1 0 -
Is IVBXF or ZLAB More Risky?
Innovent Biologics, Inc. has a beta of 0.054, which suggesting that the stock is 94.576% less volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.879, suggesting its less volatile than the S&P 500 by 12.141%.
-
Which is a Better Dividend Stock IVBXF or ZLAB?
Innovent Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innovent Biologics, Inc. pays -- of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IVBXF or ZLAB?
Innovent Biologics, Inc. quarterly revenues are --, which are smaller than Zai Lab Ltd. quarterly revenues of $116.2M. Innovent Biologics, Inc.'s net income of -- is lower than Zai Lab Ltd.'s net income of -$36M. Notably, Innovent Biologics, Inc.'s price-to-earnings ratio is 108.69x while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovent Biologics, Inc. is 11.47x versus 4.78x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IVBXFInnovent Biologics, Inc.11.47x 108.69x -- -- ZLABZai Lab Ltd.4.78x -- $116.2M -$36M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
59
SEZL alert for Feb 27
Sezzle, Inc. [SEZL] is down 13.92% over the past day.
Buy
83
GCT alert for Feb 27
GigaCloud Technology, Inc. [GCT] is down 5.87% over the past day.
Buy
62
LMAT alert for Feb 27
LeMaitre Vascular, Inc. [LMAT] is down 4.76% over the past day.
